KRTX - Karuna Therapeutics GAAP EPS of -$2.80 misses by $0.01 revenue of $0.65M
2023-05-04 06:32:32 ET
- Karuna Therapeutics press release ( NASDAQ: KRTX ): Q1 GAAP EPS of -$2.80 misses by $0.01 .
- Revenue of $0.65M.
- Announced positive topline data from the Phase 3 EMERGENT-3 trial of KarXT in schizophrenia in the first quarter of 2023
- On track to submit New Drug Application for KarXT in schizophrenia with the U.S. FDA in the third quarter of 2023, with a launch in the second half of 2024, if approved
- Phase 3 ADEPT-2 and ADEPT-3 trials of KarXT in psychosis in Alzheimer’s disease to initiate in the second half of 2023
- $1.5 billion in cash expected to fund operations through 2026.
For further details see:
Karuna Therapeutics GAAP EPS of -$2.80 misses by $0.01, revenue of $0.65M